Core Insights - The article highlights the increasing prevalence of heart valve diseases in China, particularly among the aging population, and the need for improved screening, diagnosis, and treatment options [1][2][4]. Group 1: Prevalence and Impact - Heart valve diseases have become a significant public health issue in China, affecting approximately 25 million people, with about 1 in 10 seniors over 65 years old suffering from these conditions [1][4]. - The most common heart valve disease in China is mitral valve disease, with a notable increase in aortic stenosis cases among the elderly [3][4]. Group 2: Treatment Challenges - Despite advancements in interventional treatments, the screening, early diagnosis, and treatment rates for heart valve diseases remain low, with less than 40% of patients receiving surgical treatment even in hospital settings [2][5]. - High-risk patients, particularly the elderly with multiple comorbidities, often face increased surgical risks and may opt for conservative treatment instead of surgery [5][9]. Group 3: Technological Advancements - Recent innovations in medical devices and interventional techniques have provided more treatment options, including minimally invasive procedures that are now being adopted in various healthcare facilities [7][8]. - The inclusion of heart valve interventions in insurance coverage has improved accessibility to these new technologies, encouraging hospitals to develop relevant specialties [8][9]. Group 4: Screening and Diagnosis - The article emphasizes the need for better awareness and training among healthcare providers to improve the screening rates for heart valve diseases, as many patients are diagnosed late in the disease progression [6][9]. - Routine echocardiograms have been included in health check-ups in several regions, aiding in the early detection of heart diseases [6]. Group 5: Personalized Treatment Approaches - The development of new bioprosthetic valves with extended lifespans allows for more personalized treatment strategies, reducing the need for lifelong anticoagulation therapy in younger patients [10][11]. - The focus is shifting towards determining the most beneficial treatment strategies for patients, considering their individual risk profiles and health conditions [11].